Multiple public health authorities have given insight to the timing of Zika vaccine development, with the WHO now stating that any vaccine may be too late for the current outbreak, a similar situation to the one the world experienced in the Ebola epidemic.
Following Mitsubishi Tanabe's announcement that its tobacco-based flu vaccine could hit the market by 2018 or 2019, a GlobalData analyst has lauded the Japanese company's candidate as poised to "take over" the flu vaccine market from traditional egg-based vaccines.
Citing "seriously flawed" methodology and "unjustified" claims, the journal Vaccine has permanently withdrawn a previously published study critical of Merck's Gardasil.
Widening the field further, Vaxart, Immunovaccine and Mayo Clinic are joining a slew of biotechs and pharmas either exploring or embarking on Zika vaccine development.
Vaccine companies and research organizations worldwide continue to race against Zika, with a new entrant emerging in Novavax. The biotech announced it's conducting preliminary Zika research in a week that saw several other developments in the field.
Several players are working on vaccines for Middle East respiratory syndrome (MERS), including the NIH and tandem GeneOne and Inovio, both of which had successful animal trials for their candidates. Now, a new study out of South Korea--showing that the MERS virus mutated during the outbreak--could help vaccine developers pinpoint their target on the surface of the MERS virus.
While it doesn't yet market any products, Inovio continues to be the Zika vaccine front-runner, reporting that its experimental jab induced a "robust and durable" immune response in mice.
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine.
Merck, GlaxoSmithKline and public health officials in the United States have some big new numbers to tout to promote HPV vaccination. On Monday, a group of federal researchers said that since the introduction of Gardasil in 2006, HPV infection rates in teenage girls have fallen by nearly two-thirds.
Zika developments continued at an accelerated pace this week with the WHO saying that India's Bharat Biotech and the U.S. National Institutes of Health are farthest along in vaccine development.